Literature DB >> 10068600

Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection.

A Maeda1, H Wakiguchi, W Yokoyama, H Hisakawa, T Tomoda, T Kurashige.   

Abstract

Chronic active Epstein-Barr virus infection (CAEBV) is a severe illness with unusual EBV activation that persists for years, and its pathogenesis is largely unknown. After the creation of an accurate and reproducible polymerase chain reaction system to quantify EBV DNA, virus loads in peripheral blood lymphocytes (PBL) were determined in 54 children: 15 with CAEBV, 16 with infectious mononucleosis (IM), and 23 healthy children. Children with CAEBV and those with IM had high virus loads. Lower loads were detected in 47% of seropositive healthy donors. There were two distinct differences between children with CAEBV and those with IM: The former had greater viral replication (10(3)-10(7) copies/2.5x10(5) PBL) than those with IM, and viral replication declined in children with IM whereas active replication persisted for years in subjects with CAEBV. Persisting high virus loads are a possible diagnostic criterion for CAEBV. EBV loads may enable classification and prognosis of EBV infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068600     DOI: 10.1086/314691

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 2.  The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability.

Authors:  Gerwyn Morris; Michael Berk; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-06-17       Impact factor: 5.590

3.  Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease.

Authors:  S Ohga; E Kubo; A Nomura; H Takada; N Suga; E Ishii; A Suminoe; T Inamitsu; A Matsuzaki; N Kasuga; T Hara
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

4.  Biclonal expansion of T cells infected with monoclonal Epstein-Barr virus (EBV) in a patient with chronic, active EBV infection.

Authors:  S Toyabe; W Harada; M Uchiyama
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

5.  Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus.

Authors:  R T Hayden; K M Hokanson; S B Pounds; M J Bankowski; S W Belzer; J Carr; D Diorio; M S Forman; Y Joshi; D Hillyard; R L Hodinka; M N Nikiforova; C A Romain; J Stevenson; A Valsamakis; H H Balfour
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

6.  EBV Chronic Infections.

Authors:  Pizzigallo Eligio; Racciatti Delia; Gorgoretti Valeria
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-10       Impact factor: 2.576

7.  Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations.

Authors:  Christopher P Fox; Claire Shannon-Lowe; Martin Rowe
Journal:  Herpesviridae       Date:  2011-09-07

8.  Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study.

Authors:  Kristin H Johnson; Chiu-Ho Webb; David O Schmeling; Richard C Brundage; Henry H Balfour
Journal:  Clin Transl Immunology       Date:  2016-05-13

9.  Development of a Nomogram to Predict the Risk of Chronic Active Epstein-Barr Virus Infection Progressing to Hemophagocytic Lymphohistiocytosis.

Authors:  Xiaodan He; Jingshi Wang; Deli Song; Zhao Wang
Journal:  Front Med (Lausanne)       Date:  2022-02-04

10.  Epstein-Barr Virus-Associated Vesiculopapular Eruption on the Face of a Patient with Natural Killer T Cell Lymphoma.

Authors:  Ji Soo Lim; Tae Min Kim; Kwang Hyun Cho
Journal:  Ann Dermatol       Date:  2017-08-25       Impact factor: 1.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.